Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Obi L Griffith

Showing results (141-150 of 175) with videos related to

Pageof 18
Sort By:
Blood Advances|October 17, 2022
Distinct clonal identities of B-ALLs arising after lenolidomide therapy for multiple myelomaErica K Barnell, Zachary L Skidmore, Kenneth F Newcomer, et al.
Cell Systems|December 9, 2015
Optimizing cancer genome sequencing and analysisMalachi Griffith, Christopher A Miller, Obi L Griffith, et al.
Science Immunology|June 28, 2024
Cytokines drive the formation of memory-like NK cell subsets via epigenetic rewiring and transcriptional regulationJennifer A Foltz, Jennifer Tran, Pamela Wong, et al.
Cancer Cell|September 8, 2025
Large B cell lymphoma microenvironment archetype profilesXubin Li, Kartik Singhal, Qing Deng, et al.
The Journal of Clinical Investigation|June 6, 2023
T-BET and EOMES sustain mature human NK cell identity and antitumor functionPamela Wong, Jennifer A Foltz, Lily Chang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2017
NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast CancerCynthia X Ma, Feng Gao, Jingqin Luo, et al.
Nature Communications|September 19, 2018
Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancerAlex H Wagner, Siddhartha Devarakonda, Zachary L Skidmore, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 7, 2017
A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <i>PIK3CA</i>-Mutant ER-Positive and HER2-Negative Breast CancerCynthia X Ma, Vera Suman, Matthew P Goetz, et al.
Genome Biology|August 11, 2010
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitorsSteven Jm Jones, Janessa Laskin, Yvonne Y Li, et al.
Nature Communications|September 6, 2018
The prognostic effects of somatic mutations in ER-positive breast cancerObi L Griffith, Nicholas C Spies, Meenakshi Anurag, et al.
Pageof 18

Showing results (141-150 of 175) with videos related to

Sort By:
Pageof 18
Blood Advances|October 17, 2022
Distinct clonal identities of B-ALLs arising after lenolidomide therapy for multiple myelomaErica K Barnell, Zachary L Skidmore, Kenneth F Newcomer, et al.
Cell Systems|December 9, 2015
Optimizing cancer genome sequencing and analysisMalachi Griffith, Christopher A Miller, Obi L Griffith, et al.
Science Immunology|June 28, 2024
Cytokines drive the formation of memory-like NK cell subsets via epigenetic rewiring and transcriptional regulationJennifer A Foltz, Jennifer Tran, Pamela Wong, et al.
Cancer Cell|September 8, 2025
Large B cell lymphoma microenvironment archetype profilesXubin Li, Kartik Singhal, Qing Deng, et al.
The Journal of Clinical Investigation|June 6, 2023
T-BET and EOMES sustain mature human NK cell identity and antitumor functionPamela Wong, Jennifer A Foltz, Lily Chang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2017
NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast CancerCynthia X Ma, Feng Gao, Jingqin Luo, et al.
Nature Communications|September 19, 2018
Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancerAlex H Wagner, Siddhartha Devarakonda, Zachary L Skidmore, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 7, 2017
A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <i>PIK3CA</i>-Mutant ER-Positive and HER2-Negative Breast CancerCynthia X Ma, Vera Suman, Matthew P Goetz, et al.
Genome Biology|August 11, 2010
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitorsSteven Jm Jones, Janessa Laskin, Yvonne Y Li, et al.
Nature Communications|September 6, 2018
The prognostic effects of somatic mutations in ER-positive breast cancerObi L Griffith, Nicholas C Spies, Meenakshi Anurag, et al.
Pageof 18